Terms: = Brain cancer AND MEN1, ENSG00000133895, 4221
300 results:
1. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract] [Full Text] [Related]
2. Genetic Testing in Hereditary Pituitary Tumors.
Akkuş G; Korbonits M
Arch Med Res; 2023 Dec; 54(8):102920. PubMed ID: 38007383
[TBL] [Abstract] [Full Text] [Related]
3. [Corticotropin-producing pheochromocytoma in multiple endocrine neoplasia type 1].
Rebrova DV; Grigorova SI; Vorokhobina NV; Zgoda EA; Novokshonov KY; Feofanova SG; Rusakov VF; Krasnov LM; Fedorov EA; Chinchuk IK; Shikhmagomedov SS; Pushkaruk AA; Sleptsov IV
Probl Endokrinol (Mosk); 2023 Nov; 69(5):55-64. PubMed ID: 37968952
[TBL] [Abstract] [Full Text] [Related]
4. Genetic testing in prolactinomas: a cohort study.
Boukerrouni A; Cuny T; Anjou T; Raingeard I; Ferrière A; Grunenwald S; Maïza JC; Marquant E; Sahakian N; Fodil-Cherif S; Salle L; Niccoli P; Randrianaivo H; Sonnet E; Chevalier N; Thuillier P; Vezzosi D; Reynaud R; Dufour H; Brue T; Tabarin A; Delemer B; Kerlan V; Castinetti F; Barlier A; Romanet P
Eur J Endocrinol; 2023 Dec; 189(6):567-574. PubMed ID: 37956455
[TBL] [Abstract] [Full Text] [Related]
5. Clinical Factors Predicting Multiple Endocrine Neoplasia Type 1 and Type 4 in Patients with Neuroendocrine Tumors.
Faggiano A; Fazzalari B; Mikovic N; Russo F; Zamponi V; Mazzilli R; Guarnieri V; Piane M; Visco V; Petrucci S
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761922
[TBL] [Abstract] [Full Text] [Related]
6. The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the
Vroonen L; Beckers A; Camby S; Cuny T; Beckers P; Jaffrain-Rea ML; Cogne M; Naves L; Ferriere A; Romanet P; Elenkova A; Karhu A; Brue T; Barlier A; Pétrossians P; Daly AF
Front Endocrinol (Lausanne); 2023; 14():1242588. PubMed ID: 37711900
[TBL] [Abstract] [Full Text] [Related]
7. A Japanese Family Meeting the Clinical Diagnostic Criteria for men1 with a men1 Variant of Uncertain Significance.
Matsubayashi H; Kiyozumi Y; Harada R; Mukaigawa T; Sugiura T; Ishiwatari H; Sato J; Niiya F; Nakashima K; Kado N; Nishimura S; Honda G; Ohike N
Intern Med; 2024 Apr; 63(8):1119-1123. PubMed ID: 37661450
[TBL] [Abstract] [Full Text] [Related]
8. Neuroendocrine tumors in a patient with multiple endocrine neoplasia type 1 syndrome: A case report and review of the literature.
Deng J; Liao X; Cao H
Medicine (Baltimore); 2023 Jul; 102(29):e34350. PubMed ID: 37478229
[TBL] [Abstract] [Full Text] [Related]
9. brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes.
Capitanio JF; Mortini P
Adv Exp Med Biol; 2023; 1405():645-672. PubMed ID: 37452957
[TBL] [Abstract] [Full Text] [Related]
10. [Rare forms of hereditary endocrine neoplasia: co-existence of pituitary adenoma and pheochromocytoma/paraganglioma].
Mamedova EO; Lisina DV; Belaya ZE
Probl Endokrinol (Mosk); 2023 May; 69(2):24-30. PubMed ID: 37448268
[TBL] [Abstract] [Full Text] [Related]
11. Sporadic pituitary adenoma with somatic double-hit loss of men1.
Hong CS; Alanya H; DiStasio M; Boulware SD; Rimmer RA; Omay SB; Erson-Omay EZ
Pituitary; 2023 Aug; 26(4):488-494. PubMed ID: 37438451
[TBL] [Abstract] [Full Text] [Related]
12. Expressions of Cushing's syndrome in multiple endocrine neoplasia type 1.
Simonds WF
Front Endocrinol (Lausanne); 2023; 14():1183297. PubMed ID: 37409236
[TBL] [Abstract] [Full Text] [Related]
13. Traits of Patients With Pituitary Tumors in Multiple Endocrine Neoplasia Type 1 and Comparing Different Mutation Status.
Lin KY; Kuo YT; Cheng MF; Chen PL; Wang HP; Cheng TY; Chang CH; Kao HF; Yang SH; Li HY; Lin CH; Chou YT; Chung AK; Wu WC; Lu JY; Wang CY; Hsih WH; Wen CY; Yang WS; Shih SR
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1532-e1541. PubMed ID: 37390813
[TBL] [Abstract] [Full Text] [Related]
14. Pituitary Tumorigenesis-Implications for Management.
Vamvoukaki R; Chrysoulaki M; Betsi G; Xekouki P
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109772
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and molecular features of four Brazilian families with multiple endocrine neoplasia type 1.
Miranda ISM; Valadares LP; Barra GB; Mesquita PG; de Santana LB; de Castro LF; Rita THS; Naves LA
Front Endocrinol (Lausanne); 2023; 14():1117873. PubMed ID: 36967793
[TBL] [Abstract] [Full Text] [Related]
16. Pituitary tumours: molecular and genetic aspects.
De Sousa SMC; Lenders NF; Lamb LS; Inder WJ; McCormack A
J Endocrinol; 2023 Jun; 257(3):. PubMed ID: 36951812
[TBL] [Abstract] [Full Text] [Related]
17.
Trofimiuk-Müldner M; Domagała B; Sokołowski G; Skalniak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2023; 14():1098367. PubMed ID: 36843582
[TBL] [Abstract] [Full Text] [Related]
18. Pediatric growth hormone and prolactin-secreting tumor associated with an
Alexandre MI; Faria CC; Gomes A; Bugalho MJ
J Pediatr Endocrinol Metab; 2023 Feb; 36(2):199-202. PubMed ID: 36597712
[TBL] [Abstract] [Full Text] [Related]
19. Rare clinical manifestation of multiple endocrine neoplasia type 1.
Petriczko E; Marcinkiewicz K; Prokurat A; Sagan L; Malkowski B; Biczysko-Mokosa A; Horodnicka-Jozwa A; Andrysiak-Mamos E; Syrenicz A; Kostrzeba E; Walczak M
Neuro Endocrinol Lett; 2022 Nov; 43(4):199-207. PubMed ID: 36528881
[TBL] [Abstract] [Full Text] [Related]
20. Germline CDKN1B variant type and site are associated with phenotype in MEN4.
Halperin R; Arnon L; Nasirov S; Friedensohn L; Gershinsky M; Telerman A; Friedman E; Bernstein-Molho R; Tirosh A
Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36256846
[TBL] [Abstract] [Full Text] [Related]
[Next]
